Get the full picture
Sign in to uncover key details.
Curis
Highly Engaged Employees
Highly Engaged EmployeesChemicals & Related Products · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
128 Spring St Ste 500 Bldg C, Lexington,...Phone Number
(617) 503-6500Website
www.curis.comRevenue
<$5 MillionStock Symbol
CRISIndustry
About Curis
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts, focused on discovering, developing, and commercializing innovative cancer therapeutics. Its clinical-stage pipeline includes emavusertib, an oral IRAK4 kinase inhibitor being studied for relapsed or refractory hematologic malignancies, and fimepinostat, a dual HDAC and PI3K inhibitor for diffuse large B-cell lymphoma. Curis also collaborates with Aurigene Discovery Technologies on immuno-oncology and precision oncology programs and has previously partnered with Genentech and Roche on cancer therapeutics.Explore more
Curis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Curis
Compare insights from companies similar to Curis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Curis Tech Stack
A closer look at the technologies used by Curis
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curis
Sign Up For FreeTo access detailed company insights
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts, focused on discovering, developing, and commercializing innovative cancer therapeutics. Its clinical-stage pipeline includes emavusertib, an oral IRAK4 kinase inhibitor being studied for relapsed or refractory hematologic malignancies, and fimepinostat, a dual HDAC an... Read More
